Commerzbank Aktiengesellschaft FI boosted its position in shares of Bioverativ Inc (NASDAQ:BIVV) by 18.0% during the 4th quarter, HoldingsChannel reports. The firm owned 11,613 shares of the biotechnology company’s stock after buying an additional 1,773 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Bioverativ were worth $626,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of BIVV. Wells Fargo & Company MN purchased a new position in Bioverativ during the 3rd quarter worth approximately $124,500,000. Woodford Investment Management Ltd purchased a new position in Bioverativ during the 3rd quarter worth approximately $85,455,000. Jackson Square Partners LLC purchased a new position in Bioverativ during the 3rd quarter worth approximately $99,336,000. Old Mutual Global Investors UK Ltd. purchased a new position in Bioverativ during the 3rd quarter worth approximately $96,827,000. Finally, ValueAct Holdings L.P. purchased a new position in shares of Bioverativ during the 3rd quarter valued at $72,514,000. Hedge funds and other institutional investors own 95.14% of the company’s stock.
Shares of Bioverativ Inc (NASDAQ BIVV) opened at $103.50 on Tuesday. Bioverativ Inc has a 52 week low of $41.88 and a 52 week high of $104.30.
COPYRIGHT VIOLATION WARNING: “Bioverativ Inc (BIVV) Shares Bought by Commerzbank Aktiengesellschaft FI” was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.com-unik.info/2018/02/06/bioverativ-inc-bivv-shares-bought-by-commerzbank-aktiengesellschaft-fi.html.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.